Hoe kunnen we klinische richtlijnen voor de preventie en behandeling van cardiovasculaire en andere (late-onset) ziekten zoals kanker en ontstekingsziekten het meest effectief implementeren?

How can we most effectively implement clinical guidelines to prevent and treat cardiovascular and other late-onset diseases such as cancer and inflammatory diseases? Cardiovascular disease, presenting acutely as stroke, myocardial infarction and/or heart failure, is still the most important cause of morbidity and mortality globally, despite major advances in acute management of ischemic events and treatment of atherosclerosis. To reverse this chronic process and to prevent acute events resulting from plaque rupture and atherothrombosis, is still a major challenge. New insights in the pathogenesis of atherosclerosis, in particular the role of inflammation, provides potential new targets for therapy. In addition, organ damage resulting from these ischemic events needs to be minimized. Also in the field of the pathophysiology of ischemia-reperfusion injury, preclinical research has provided important new insights